دورية أكاديمية
Exploring DNA Methylation for Prognosis and Analyzing the Tumor Microenvironment in Pleomorphic Xanthoastrocytoma
| العنوان: | Exploring DNA Methylation for Prognosis and Analyzing the Tumor Microenvironment in Pleomorphic Xanthoastrocytoma |
|---|---|
| المؤلفون: | Tang, Karen, Kurland, David, Vasudevaraja, Varshini, Serrano, Jonathan, Delorenzo, Michael, Radmanesh, Alireza, Thomas, Cheddhi, Spino, Marissa, Gardner, Sharon, Allen, Jeffrey C, Nicolaides, Theodore, Osorio, Diana S, Finlay, Jonathan L, Boué, Daniel R, Snuderl, Matija |
| المساهمون: | Friedberg Charitable Foundation, Making Headway Foundation, NYU CTSA, National Center for Advancing Translational Sciences, NIH |
| المصدر: | Journal of Neuropathology & Experimental Neurology ; volume 79, issue 8, page 880-890 ; ISSN 0022-3069 1554-6578 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Cellular and Molecular Neuroscience, Neurology (clinical), Neurology, General Medicine, Pathology and Forensic Medicine |
| الوصف: | Pleomorphic xanthoastrocytoma (PXA) is a rare type of brain tumor that affects children and young adults. Molecular prognostic markers of PXAs remain poorly established. Similar to gangliogliomas, PXAs show prominent immune cell infiltrate, but its composition also remains unknown. In this study, we correlated DNA methylation and BRAF status with clinical outcome and explored the tumor microenvironment. We performed DNA methylation in 21 tumor samples from 18 subjects with a histological diagnosis of PXA. MethylCIBERSORT was used to deconvolute the PXA microenvironment by analyzing the associated immune cell-types. Median age at diagnosis was 16 years (range 7–32). At median follow-up of 30 months, 3-year and 5-year overall survival was 73% and 71%, respectively. Overall survival ranged from 1 to 139 months. Eleven out of 18 subjects (61%) showed disease progression. Progression-free survival ranged from 1 to 89 months. Trisomy 7 and CDKN2A/B (p16) homozygous deletion did not show any association with overall survival (p = 0.67 and p = 0.74, respectively). Decreased overall survival was observed for subjects with tumors lacking the BRAF V600E mutation (p = 0.02). PXAs had significantly increased CD8 T-cell epigenetic signatures compared with previously profiled gangliogliomas (p = 0.0019). The characterization of immune cell-types in PXAs may have implications for future development of immunotherapy. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/jnen/nlaa051 |
| الإتاحة: | https://doi.org/10.1093/jnen/nlaa051Test https://academic.oup.com/jnen/article-pdf/79/8/880/40419873/jnen_79_8_880.pdfTest |
| حقوق: | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_modelTest |
| رقم الانضمام: | edsbas.21FAD019 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/jnen/nlaa051 |
|---|